Hoppegarten

Researchers are evaluating the retention rates of two treatments, upadacitinib UPA and tumor necrosis factor inhibitors TNFi, in adults with moderate to severe active rheumatoid arthritis RA in a real-world setting in Germany. This observational study aims to compare how long patients stay on each treatment when prescribed according to local standards and labels. About 678 participants will be enrolled over approximately 24 months, with total study duration lasting up to 48 months. Participants will receive either upadacitinib or a TNFi treatment as prescribed by their physicians following local regulatory and reimbursement guidelines. The decision to treat with UPA or TNFi is made independently of the study and before recruitment. The study does not assign treatments but observes patients already prescribed these therapies. During the study, researchers will monitor participants for up to 24 months to measure retention rates of the treatments. Data collection will include regular assessments according to routine care practices to track treatment persistence. The study focuses on real-world outcomes without altering standard treatment or care. Safety monitoring and follow-up will be conducted as part of usual medical care.

Researchers are conducting a prospective, multicenter, observational study in Germany to evaluate the clinical value and impact of serum neurofilament light sNfL as a prognostic marker for disease activity in patients with relapsing Multiple Sclerosis MS. The study focuses on patients who have received category 1 disease-modifying therapies DMTs and monitors routinely assessed sNfL values to better understand their role in patient management. Participants in the study either continue their current category 1 DMT treatment or switch to ofatumumab based on their physicians clinical judgment, independent of study enrollment. Category 1 DMTs include medications such as dimethylfumarate, diroximelfumarate, glatiramer acetate, interferon beta, and teriflunomide. Data will be collected over a maximum period of 24 months during routine clinical visits, with no specific protocol dictating observation frequency or diagnostic procedures. During the study, researchers will gather primary data including sNfL test results and track various outcomes like disease activity, treatment adherence, patient-reported fatigue, quality of life, and treatment satisfaction. Assessments will align with standard care practices and guidelines, and the study will measure outcomes at baseline, 12 months, and 24 months. The study aims to provide insights into the use of sNfL in clinical practice and its implications for managing relapsing MS.